Insmed (INSM) Reports Q2 Loss of $0.72/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Insmed Reports Second Quarter 2017 Financial Results and Provides Business Update
August 3, 2017 7:31 AM EDTOn Track to Report Top-Line Results from Phase 3 CONVERT Study in September plus or minus one month  Plan to Initiate Enrollment of Phase 2 Dose-ranging Study of INS1007 in Non-Cystic Fibrosis (non-CF) Bronchiectasis in the Second Half of 2017 U.S. Food and Drug Administration (FDA) Provides Established Name for Lead Development Program ALIS (amikacin liposome inhalation suspension)
BRIDGEWATER, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) --  Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company focused on the unmet... More
